Particle.news

France Authorizes Ricimed, Fabentech’s Antidote to Ricin

The company reports it is moving into sales for state preparedness with contracts already signed in Europe.

Overview

  • Fabentech said it has received French market authorization to commercialize Ricimed for treating ricin poisoning.
  • The company says the polyclonal antibody therapy targets and neutralizes ricin before it causes irreversible harm.
  • More than €20 million in multi‑year agreements have been signed with several European countries for preventive stockpiling, according to the firm.
  • This marks the first authorized ricin countermeasure in France and positions the product primarily for emergency reserves.
  • Fabentech cites support from France’s defense authorities, the EU HERA program, and an early European Investment Bank loan, as ricin continues to be viewed as a bioterror risk.